報價延遲最少15分鐘:2025/05/31 15:56 EDT
|
|
|
|
|
||||||||||||
|
|
|
|
|
2.56 
|
|
|
| 價值評估 |
|
盈利(現時/預測)
-2.54/-0.14
|
|
企業價值
4.23M
|
| 資產負債 |
|
每股賬面淨值
0.65
|
| 現金流量 |
|
現金流量率
--
|
| 損益表 |
|
收益
10.00K
|
|
每股收益
1.78
|
|
同行比較
|
||||||||||||||||||||||||||||||||||||||||||||||||
|
報價延遲最少15分鐘：2025/05/31 15:56 EDT
同行比較之報價最少15分鐘延遲
|
業務概覽
|
|||
| Alaunos Therapeutics Inc is a clinical-stage cellular immuno-oncology company dedicated to the treatment of solid tumors through adoptive TCR-T cell therapy. It strikes cancer at its core by engineering cell therapies that target Neoantigens arising from genomic mutations. It has a single reportable and operating segment related to biopharmaceutical research and development. |